The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmaceutical Research

• Publication date

  2013-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s11095-012-0921-3PMID 23135825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys

  2012cited by this paper
• Elimination of β-mannose glycan structures in Pichia pastoris.

  2011cited by this paper
• Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

  2011cited by this paper
• Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

  2011cited by this paper
• Strategies for extended serum half-life of protein therapeutics.

  2011cited by this paper
• Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism

  2011cited by this paper
• Anti-TNF therapy.

  2011cited by this paper
• Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies

  2011cited by this paper
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

  2010cited by this paper
• Biopharmaceutical benchmarks 2010

  2010cited by this paper
• Tumor Necrosis Factor and Anti-Tumor Necrosis Factor Therapies

  2010cited by this paper
• An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G.

  2010cited by this paper
• Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding*

  2009cited by this paper
• Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins

  2008cited by this paper
• Use of high-performance anion exchange chromatography with pulsed amperometric detection for O-glycan determination in yeast

  2008cited by this paper
• Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates

  2007cited by this paper
• Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins

  2006cited by this paper
• Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose.

  2004cited by this paper
• Production of complex human glycoproteins in yeast.

  2003cited by this paper
• Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris

  2003cited by this paper
• Filamentous fungi as cell factories for heterologous protein production.

  2002cited by this paper
• Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP).

  2001cited by this paper
• The mannose receptor is a pattern recognition receptor involved in host defense.

  1998cited by this paper
• High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization.

  1997cited by this paper
• Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.

  1995cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor.

  1993cited by this paper
• Trafficking of asialoglycoproteins and the asialoglycoprotein receptor.

  1991cited by this paper
• On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action.

  1974cited by this paper
• Studies on the role of sialic acid in the physical and biological properties of erythropoietin.

  1972cited by this paper
• On the mechanism of erythropoietin-induced differentiation

  1965cited by this paper
• Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions

  1960cited by this paper

• Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study

  2024cites this paper
• Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation

  2024cites this paper
• Applications of the Methylotrophic Yeast Komagataella phaffii in the Context of Modern Biotechnology

  2024cites this paper
• Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content.

  2023cites this paper
• New Opportunities in Glycan Engineering for Therapeutic Proteins

  2022cites this paper
• Challenges and Opportunities for the Large-Scale Chemoenzymatic Glycoengineering of Therapeutic N-Glycosylated Monoclonal Antibodies

  2022cites this paper
• The use of fungi for the production of biotechnological products in the field of health

  2022cites this paper
• Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing

  2022cites this paper
• Strains and Molecular Tools for Recombinant Protein Production in Pichia pastoris.

  2022cites this paper
• Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo.

  2022cites this paper
• Design of a novel switchable antibody display system in Pichia pastoris

  2022cites this paper
• Glycosylation of immunoglobin G in tumors: Function, regulation and clinical implications.

  2022cites this paper
• O-glycosylation and its role in therapeutic proteins

  2022cites this paper
• Glycoengineering Chinese hamster ovary cells: a short history

  2021cites this paper
• Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

  2021cites this paper
• Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies

  2021cites this paper
• Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

  2021cites this paper
• The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics.

  2021cites this paper
• IgG N-glycans.

  2021cites this paper
• Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method

  2021cites this paper
• Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate.

  2021cites this paper
• Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris

  2020cites this paper
• Structural insight and stability of TNFR-Fc fusion protein (Etanercept) produced by using transgenic silkworms

  2020cites this paper
• The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

  2020cites this paper
• At-line high throughput site-specific glycan profiling using targeted mass spectrometry

  2020cites this paper
• Antibody glycosylation: impact on antibody drug characteristics and quality control

  2020cites this paper
• Future Science Group

  2019cites this paper
• Insights into the loss of protein sialylation in an fc-fusion protein-producing CHO cell bioprocess

  2019cites this paper
• N‐glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance

  2019cites this paper
• Production and secretion of heterologous immunomodulators in bacteroides thetaiotaomicron

  2019influential citation
• The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins.

  2019cites this paper
• Quantitative characterization of intact sialylated O-glycans with MALDI-MS for protein biotherapeutics

  2018cites this paper
• Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept

  2018cites this paper
• The yeast stands alone: the future of protein biologic production.

  2018cites this paper
• Purification Methods for Recombinant Factor VIII Expressed in Human Liver SK-Hep Cells.

  2018cites this paper
• Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies.

  2018cites this paper
• Improving Immunotherapy Through Glycodesign

  2018cites this paper
• Engineering of Yeast Glycoprotein Expression.

  2018cites this paper
• Orthogonal Middle-up Approaches for Characterization of the Glycan Heterogeneity of Etanercept by Hydrophilic Interaction Chromatography Coupled to High-Resolution Mass Spectrometry.

  2018cites this paper
• Characterization and minimization of sialic acid degradation in an Fc-fusion protein-producing CHO cell bioprocess

  2018cites this paper
• Controlling Glycosylation in Fusion Protein Manufacturing to Generate Potent Biobetters

  2017cites this paper
• Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

  2017cites this paper
• Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties

  2017cites this paper
• Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

  2017cites this paper
• N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

  2016cites this paper
• Functionality determination and characterization of an angiogenesis-inhibiting fusion protein

  2016cites this paper
• Role of Glycans in Cancer Cell Death: A Deadly Relationship

  2016cites this paper
• Fc gamma receptors: glycobiology and therapeutic prospects

  2016cites this paper
• Immunoglobulin-based strategies for half-life extension of recombinant proteins

  2015cites this paper
• Galactose supplementation enhance sialylation of recombinant Fc-fusion protein in CHO cell: an insight into the role of galactosylation in sialylation

  2015cites this paper
• Engineering yeast for producing human glycoproteins: where are we now?

  2015cites this paper
• Engineering β1,4-galactosyltransferase I to reduce secretion and enhance N-glycan elongation in insect cells.

  2015cites this paper
• Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

  2015cites this paper
• Yeast Metabolic Engineering

  2014cites this paper
• Strains and molecular tools for recombinant protein production in Pichia pastoris.

  2014cites this paper
• Pharmacokinetic and pharmacodynamic challenges of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  2014cites this paper
• Biopharmaceutical discovery and production in yeast.

  2014cites this paper
• In vitro enzymatic treatment to remove O-linked mannose from intact glycoproteins

  2014cites this paper
• Enabling global access to high-quality biopharmaceuticals

  2013cites this paper
• Deciphering O-glycomics for the development and production of biopharmaceuticals

  2013cites this paper
• Characterization of the Pichia pastoris Protein-O-mannosyltransferase Gene Family

  2013cites this paper
• Cell Culture‐Based Production

  2013cites this paper
• Production of sialylated O-linked glycans in Pichia pastoris.

  2013cites this paper